Natera, Inc. (NTRA)

Natera's stock price has experienced several notable events in the past six months. The company reported strong Q2 and Q3 2025 financial results, exceeding expectations and raising its 2025 annual revenue outlook, and preliminary Q4 revenue for 2025 also exceeded consensus. Multiple analysts have reiterated "Buy" or "Overweight" ratings and raised price targets for NTRA. Natera announced the acquisition of Foresight Diagnostics, which was viewed positively by investors. A collaboration with Exelixis on the STELLAR-316 phase 3 trial for colorectal cancer was announced. Natera voluntarily dismissed its appeal in a patent case it had lost to NeoGenomics, and a jury issued a decision in Guardant Health's favor in a false advertising case against Natera. Significant insider selling has been noted, and Natera reported an EPS miss in Q3 2025.

Explicit detailed information regarding the demand seasonality for Natera, Inc.'s products and services is not readily available. However, the company has demonstrated strong and accelerating revenue growth and consistent growth in test volumes, suggesting a generally strong and increasing demand for Natera's offerings, rather than pronounced seasonal fluctuations being a primary driver.

Natera, Inc. is a clinical genetic testing company specializing in non-invasive, cell-free DNA (cfDNA) testing technology, operating within the molecular diagnostics sector with a focus on women's health, oncology, and organ health. The company's technology integrates molecular biology techniques with bioinformatics software and artificial intelligence to analyze DNA from blood samples. Natera offers products and services such as the Panorama Non-Invasive Prenatal Test (NIPT), Vistara single-gene NIPT, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, non-invasive prenatal paternity testing, Signatera for detecting molecular residual disease (MRD) and monitoring cancer recurrence, and Prospera for assessing organ rejection risk in transplant patients. Natera also provides Constellation, a cloud-based software platform for laboratory customers.

Natera, Inc. is headquartered in Austin, Texas, and operates CAP-accredited and CLIA-certified laboratories in San Carlos, California, and Austin, Texas. Through Foresight Diagnostics, it also operates an ISO 27001-certified and CAP-accredited laboratory in Boulder, Colorado. The company serves healthcare providers, hospitals, fertility clinics, and biopharmaceutical partners in the United States and international markets. A significant portion of shareholders are from the United States (74.76%) and the United Kingdom (13.01%).

Natera's brand reputation has been influenced by positive analyst sentiment and strategic advancements, as well as ongoing legal challenges. The company has received generally positive sentiment from analysts, with a consensus rating of "Moderate Buy" and numerous price target increases. However, Natera has faced reputation-impacting events related to litigation, including a jury ruling in favor of Guardant Health in a false advertising case and a previous case where a federal jury found Natera intentionally misled the public with false advertisements for its Prospera test.

Natera, Inc. has significant institutional ownership, with 1344 institutional owners and shareholders holding approximately 83.18% of the company. Individuals hold 3.27%, and insiders own approximately 5.63% of the stock. Major institutional shareholders include Vanguard Group Inc., Price T Rowe Associates Inc /md/, JPMorgan Chase & Co, BlackRock, Inc., Farallon Capital Management Llc, and State Street Corp.